Mid
G
GSKAI Stock Diagnostic Report
GSK's Jemperli gets FDA priority review for rectal cancer
GSK's immuno-oncology drug 'Zemphiry' has been designated as a priority review by the U.S. FDA for the indication of colorectal cancer.
View Source Article ↗AI CATALYST SCORE75 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
GSK Analysis History (Last 30 Days)